Sun Biopharma Inc. (SNBP) News
Filter SNBP News Items
SNBP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SNBP News From Around the Web
Below are the latest news stories about Sun BioPharma Inc that investors may wish to consider to help them evaluate SNBP as an investment opportunity.
Sun Biopharma prices $10.5M equity offeringSun BioPharma (SNBP) has priced public offering of 2,545,454 common stock and the same number of warrants at $4.125/share and warrant, for gross proceeds of ~$10.5M.Each warrant entitles the holder to purchase one share of common stock at $4.54 /share. The company will kick-off trading today on Nasdaq Capital Market.... |
IPO Update: Sun BioPharma Presents IPO TermsQuick Take Sun BioPharma (SNBP) intends to raise $10 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is developing a treatment candidate for pancreatic cancer. SNBP is a thinly capitalized firm operating in a very difficult area of research,... |
Sun BioPharma Begins U.S. IPO PlanQuick Take Sun BioPharma (SNBP) has filed to raise $12 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical stage biopharma advancing a small molecule treatment candidate for pancreatic cancer and other solid tumors. SNBP is a tiny firm with... |
Sun BioPharma's SBP-101 Fast Track'd for type of pancreatic cancerThe FDA designates Sun BioPharma's (SNBP) lead candidate SBP-101 for Fast Track review for the treatment of patients with pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.SBP-101 is... |